Skip to main content

Chronic Cholecystitis

1
Pipeline Programs
1
Companies
3
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

JSC Valenta Pharmaceuticals
1 program
1
4-MUSTPhase 23 trials
Active Trials
NCT07594977Recruiting45Est. Jun 2027
NCT07595003Recruiting300Est. Dec 2027
NCT06842966Recruiting300Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
JSC Valenta Pharmaceuticals4-MUST
JSC Valenta Pharmaceuticals4-MUST
JSC Valenta Pharmaceuticals4-MUST

Clinical Trials (3)

Total enrollment: 645 patients across 3 trials

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Start: Dec 2025Est. completion: Dec 2027300 patients
Phase 3Recruiting

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Start: Oct 2024Est. completion: Dec 2026300 patients
Phase 2Recruiting

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers

Start: Jan 2026Est. completion: Jun 202745 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 645 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.